Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 90/100

Termination Rate

28.6%

2 terminated out of 7 trials

Success Rate

0.0%

-86.5% vs benchmark

Late-Stage Pipeline

14%

1 trials in Phase 3/4

Results Transparency

0%

1 of 0 completed with results

Key Signals

1 with results0

Data Visualizations

Phase Distribution

7Total
P 1 (4)
P 2 (2)
P 3 (1)

Trial Status

Recruiting4
Terminated2
Active Not Recruiting1

Clinical Trials (7)

Showing 7 of 7 trials
NCT03025256Phase 1Recruiting

Intravenous and Intrathecal Nivolumab in Treating Patients With Leptomeningeal Disease

NCT02506153Phase 3Active Not Recruiting

Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery

NCT05341349Phase 1Terminated

Stereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-200M for the Treatment of Melanoma Brain Metastases

NCT05098210Phase 1Recruiting

Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer

NCT03865212Phase 1Terminated

Modified Virus VSV-IFNbetaTYRP1 in Treating Patients With Stage III-IV Melanoma

NCT07155317Phase 2Recruiting

Time-of-Day Specified Immunotherapy for Advanced Melanoma, The TIME Trial

NCT04511013Phase 2Recruiting

A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases

Showing all 7 trials

Research Network

Activity Timeline